TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: neurobehavioral functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep deprivation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 52-week abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Stage 2 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Stage 1 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of agreement in risk registration for previous pregnancy complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Degree of agreement in risk registration for recommendations for doctor's consultation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Degree of agreement in risk registration for psychosocial aspects, such as anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete or almost complete remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell activation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Erythema of human skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sunburn cell formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CD1a-expressing Langerhans cells suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to termination of tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse effects of adenosine
Endpoint domain: Adverse events/effects
Primary endpoint: Overall test sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in RvE1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: patient-rated frequency of elbow pain with activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-tumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Length of hospital stay for patients with ventilator-associated pneumonia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mortality rate in patients with ventilator-associated pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: postoperative blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength of cast complete crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of corneal neovascularization (CN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of overall cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of colorectal cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Variability of fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of linoleic acid in triglycerides, cholesterol esters, and phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful rate of colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the ileocecal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in non-opioid drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum CPK‐MM activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: histologic muscle lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HPV vaccine initiation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HPV vaccination completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response to tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary kinase mutations frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal biopsy activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean area under the triazolam concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak concentration of triazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dispensing error rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pharyngeal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IL‐1β, IL‐8 and TNF‐α in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stent thrombosis events
Endpoint domain: Adverse events/effects
Primary endpoint: Jebsen‐Taylor hand function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of seasickness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adipocyte size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UCP1 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mitochondrial density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improved range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic properties (AUC(0-12))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of training sessions attended
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enlargement ratio of macular atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impaired safety of swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neopterin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kyn/trp ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for up-transfer of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: time of resolution of cobblestone papillae, lid oedema, conjunctival discharge and chemosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity and rate of recurrence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ductus arteriosus flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate and severe bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS score of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12v2 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric mean AUC of darunavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean AUC of raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective binge episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective binge episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of self-awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Rey Auditory Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean time to muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival rate at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Time for the block to reach the T‐4 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete motor blockade (Bromage score 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of PAPNET Testing System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Barthel index of activity of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in modified Rankin scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in post-stroke spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: post-PCI acute stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of false-positive (FP) screening results
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of next-round prostate cancer (PC) following an FP result
Endpoint domain: Adverse events/effects
Primary endpoint: Likelihood of participation in subsequent screening rounds
Endpoint domain: Adverse events/effects
Primary endpoint: Placement of catheter in extramembranous space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: functional hand use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EGG rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal toxicity prediction performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Genitourinary toxicity prediction performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Calgary Depression Scale for Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of classical malaria signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in specific antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consumption of sweetened drinks and packaged snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intentional walking for exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leisure screen time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: risk of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: disease-free interval (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgical field quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Catheter failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until catheter failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local control of the chest tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: central retinal thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total success rate at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with study-sponsored support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Night Driving Simulator performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to FS screening guidelines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean astigmatism vector reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conduct problem behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptom frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC function scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCG‐5 quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: student concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: student participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Gel coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol consumption
Endpoint domain: Adverse events/effects
Primary endpoint: Arrhythmogenic morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor capabilities improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased motor dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of atopic dermatitis (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost-effectiveness of outreach
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for sufentanil and ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of low oxygen saturation (SpO2<90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mitogen-induced activation of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of IL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adjusted mean trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ACQ-7 responder rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of general obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-y change in fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: R0 reoperation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: helmet use rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician injury prevention counselling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative incidence of anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patella score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pressure support delivered by the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Drop in intraoperative temperature (T c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence of lesions
Endpoint domain: Mortality/survival
Primary endpoint: Sustained lesion complete response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOTPAR 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curarisation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coughing during tracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with severe QOL impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Q‐LES‐Q total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: haemoglobin concentration of drainage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma classification improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in maintenance drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: quality-of-life questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: systolic strain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary heart disease events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-efficacy for communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: emotional intelligence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: interpersonal communication competence
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Multisite vaccine efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HDL cholesterol level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average percentage of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of moist desquamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Bone mineral density of proximal femurs of paretic limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in core temperature thresholds for vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in core temperature thresholds for shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in interthreshold range between sweating and vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat and fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(1) recovery (T75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOF ratio (0.7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in explosive strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean 6MWD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative field visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PUN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in macrophage migration inhibitory factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative reduction in FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rapid viral response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faldaprevir exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes